reports
Gemphire Therapeutics Announces Expected Closing Date of Merger with N...
Gemphire Therapeutics Announces Expected Closing Date of Merger with NeuroBo Pharmaceuticals ANN ARBOR, Mich., Dec. 30, 2019 (GLOBE NEWSWIRE) -- The pending merger between Gemphire Therapeutics Inc. (NASDAQ:GEMP) and NeuroBo Pharmaceuticals, Inc. is currently expected to close after market hours today, Monday, December 30, 2019, subject to satisfaction or waiver of all closing conditions. As previously announced, Gemphire’s stockholders voted to approve the proposals required to complete the merger transaction. In connection with these approvals, the Board of Directors of Gemphire has ap...
Gemphire Therapeutics Announces Stockholder Approval of Proposals Requ...
Gemphire Therapeutics Announces Stockholder Approval of Proposals Required for Merger with NeuroBo Pharmaceuticals ANN ARBOR, Mich., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held December 6, 2019, its stockholders approved all of the merger-related proposals, including: (i) the issuance of Gemphire common stock pursuant to the Agreement and Plan of Merger and Reorganization, dated July 24, 2019, by and among Gemp...
Gemphire Therapeutics Reports Second Quarter 2019 Financial Results an...
Gemphire Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update LIVONIA, Mich., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease, focused on orphan indications, as well as nonalcoholic fatty liver disease (NAFLD/NASH), today announced financial results for the quarter and six months ended June 30, 2019, and provided a ...
Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agre...
Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company Transaction to Create Nasdaq-listed Biotechnology Company Focused on Advancing NeuroBo’s Clinical-Stage Pipeline NeuroBo Poised to Advance Lead Drug Candidate into Phase 3 Trials for Neuropathic Pain Indications NeuroBo Recently Received Aggregate Gross Proceeds of $24.24 Million in Series B Financing Gemphire Out-Licenses Gemcabene to Beijing SL Pharmaceutical Co. for Chinese Market Companies to Host Conference Call at 8:30 a.m. ET on July 25, 2019 LIVONIA, Mich...
Gemphire Announces Top-Line Data from Familial Partial Lipodystrophy (...
Gemphire Announces Top-Line Data from Familial Partial Lipodystrophy (FPLD) Phase 2a Proof-of-Concept NAFLD/NASH Clinical Trial Gemcabene safely lowered serum triglycerides (TGs), the primary endpoint, in a subset of FPLD patients LIVONIA, Mich., June 26, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP) today announced top-line results based upon the Company’s preliminary review of the limited top-line dataset from the investigator-led Phase 2a study of adult FPLD patients evaluating efficacy, safety, and tolerability of oral gemcabene. Five FPLD patients were enrolle...
Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2018 Fina...
Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2018 Financial Results LIVONIA, Mich., March 15, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease, focused on orphan indications, as well as nonalcoholic fatty liver disease (NAFLD/NASH), today announced its financial results for the quarter and fiscal year ended December 31, 2018, and prov...
Gemphire Therapeutics Announces Review of Strategic Alternatives and P...
Gemphire Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update LIVONIA, Mich., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today announced that its Board of Directors is conducting a review of a range of strategic alternatives focused on maximizing stockholder value. The Company has engaged Ladenburg Thalmann & Co. Inc. to act as its str...
Gemphire Therapeutics Reports Third Quarter 2018 Financial Results and...
Gemphire Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update LIVONIA, Mich., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today announced financial results for the quarter and nine months ended September 30, 2018, and provided a corporate update. “During the third quarter we had several accomplishments that are important to the contin...
Gemphire Therapeutics Announces Workforce Reduction
Gemphire Therapeutics Announces Workforce Reduction LIVONIA, Mich., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), announces today that its Board of Directors has approved a workforce reduction in order to reduce costs and conserve cash resources. This decision was made in light of the previously announced request by the Food and Drug Administration (FDA) for additional p...
Gemphire Therapeutics Reports Second Quarter 2018 Financial Results an...
Gemphire Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update LIVONIA, Mich., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today announced financial results for the quarter and six months ended June 30, 2018, and provided a corporate update. “We capped off our second quarter by announcing that our INDIGO-1 trial investigating gemcaben...
Gemphire Announces Termination of Phase 2a Clinical Trial of Gemcabene...
Gemphire Announces Termination of Phase 2a Clinical Trial of Gemcabene in Pediatric NAFLD LIVONIA, Mich., Aug. 10, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), announces today that the Data and Safety Monitoring Board (DSMB) at Emory University School of Medicine overseeing the investigator-led open label Phase 2a proof-of-concept trial evaluating gemcabene in pediatric patients ...
Gemphire Announces Amended and Restated Gemcabene License Agreement wi...
Gemphire Announces Amended and Restated Gemcabene License Agreement with Pfizer Inc. LIVONIA, Mich., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today announced that it has amended and restated the license agreement with Pfizer Inc. covering gemcabene. Gemphire licensed exclusive worldwide commercial rights to gemcabene from Pfizer in an agreement signed in April 2011....
Gemphire Provides Update On Development of Gemcabene
Gemphire Provides Update On Development of Gemcabene FDA requests the Company provide additional data regarding the partial clinical hold Company continues Phase 2 development of gemcabene for NAFLD/NASH Company amends loan agreement with SVB to provide additional flexibility Conference call and webcast today, Monday, August 6, at 4:30 p.m. Eastern Time LIVONIA, Mich., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslip...
Gemcabene Meets Primary Endpoint in INDIGO-1 Study of Severe Hypertrig...
Gemcabene Meets Primary Endpoint in INDIGO-1 Study of Severe Hypertriglyceridemia (SHTG) Patients Gemcabene demonstrated statistically significant lowering of triglycerides (TGs) in SHTG Secondary endpoints achieved included statistically significant reductions in serum LDL-C, non-HDL-C, VLDL-C, apoB, apoE, apoCIII, and SAA Gemcabene showed evidence of safety and tolerability in combination with statins INDIGO-1 results further support Gemphire’s rationale for developing gemcabene as a treatment for NAFLD/NASH Conference call and webcast today, Thursday, June 28, at 4:30 p.m. Eastern Ti...
Gemphire Therapeutics to Announce Fourth Quarter and Year End 2017 Fin...
Gemphire Therapeutics to Announce Fourth Quarter and Year End 2017 Financial Results on Thursday, March 15 LIVONIA, Mich., March 13, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), today announced that it will host a conference call and live audio webcast on Thursday, March 15, 2018 at 4:30 p.m. Eastern Time to discuss financial results fo...
- Jonathan Moreland
BPL BUCKEYE PARTNERS L.P.
BKD BROOKDALE SENIOR LIVING INC.
WFC WELLS FARGO & COMPANY
VCEL VERICEL
TNDM TANDEM DIABETES CARE INC
TICC OXFORD SQUARE CAPITAL CORP
TDOC TELADOC HEALTH INC.
TCBI TEXAS CAPITAL BANCSHARES INC.
STOR STORE CAPITAL CORPORATION
PSX PHILLIPS 66
PSEC PROSPECT CAPITAL CORPORATION
PFLT PENNANTPARK FLOATING RATE CAPITAL LTD.
PBH PRESTIGE CONSUMER HEALTHCARE INC
OSIS OSI SYSTEMS INC.
OPK OPKO HEALTH INC.
NHI NATIONAL HEALTH INVESTORS INC.
MPAA MOTORCAR PARTS OF AMERICA INC.
IRT INDEPENDENCE REALTY TRUST INC.
IPHI INPHI CORPORATION
HBAN HUNTINGTON BANCSHARES INCORPORATED
HASI HANNON ARMSTRONG SUSTAINABLE INFRASTRUCTURE CAPITAL INC.
GPRO GOPRO INC. CLASS A
GOOD GLADSTONE COMMERCIAL CORPORATION
GLPI GAMING AND LEISURE PROPERTIES INC.
FSIC FS KKR CAPITAL CORP.
EPC EDGEWELL PERSONAL CARE CO.
DWCH DATAWATCH
CLR CONTINENTAL RESOURCES INC.
CEMI CHEMBIO DIAGNOSTICS INC.
AHH ARMADA HOFFLER PROPERTIES INC.
AAT AMERICAN ASSETS TRUST INC.
CSV CARRIAGE SERVICES INC.
DLTH DULUTH HOLDINGS INC. CLASS B
DM DOMINION ENERGY MIDSTREAM PARTNERS LP
GRA W R GRACE & CO
RARX RA PHARMACEUTICALS
T AT&T CORP.
GEMP GEMPHIRE THERAPEUTICS
CLCT COLLECTORS UNIVERSE INC.
ATNX ATHENEX
BCO THE BRINK'S COMPANY
ODT ODONATE THERAPEUTICS INC
COGT FLUENT INC
PBIP PRUDENTIAL BANCORP
PHIL PHI GROUP INC.
XTNT XTANT MEDICAL HOLDINGS
GRC THE GORMAN-RUPP COMPANY
- Jonathan Moreland
KRG KITE REALTY GROUP TRUST
WAIR WESCO AIRCRAFT HOLDINGS INC
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
TNDM TANDEM DIABETES CARE INC
TDOC TELADOC HEALTH INC.
SYNL SYNALLOY CORP.
RDUS RADIUS HEALTH INC.
PSEC PROSPECT CAPITAL CORPORATION
PFLT PENNANTPARK FLOATING RATE CAPITAL LTD.
PBH PRESTIGE CONSUMER HEALTHCARE INC
OPK OPKO HEALTH INC.
MPAA MOTORCAR PARTS OF AMERICA INC.
MOFG MIDWESTONE FINANCIAL GROUP
MB MINDBODY INC. CLASS A
LJPC LA JOLLA PHARMACEUTICAL COMPANY
A2N6GQ LEGACY RESERVES
A2LQV6 KKR & CO INC
IVAC INTEVAC INC.
IMMU IMMUNOMEDICS INC.
GLPI GAMING AND LEISURE PROPERTIES INC.
FSIC FS KKR CAPITAL CORP.
FRSH PAPA MURPHYS HOLDINGS
FLDM FLUIDIGM
EPC EDGEWELL PERSONAL CARE CO.
COTY COTY INC. CLASS A
BZH BEAZER HOMES USA INC.
BDGE BRIDGE BANCORP INC.
ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A.
AKAO ACHAOGEN INC.
AHH ARMADA HOFFLER PROPERTIES INC.
BW BABCOCK & WILCOX ENTERPRISES
OW0A OCWEN FINANCIAL CORPORATION
MLI MUELLER INDUSTRIES INC.
GRA W R GRACE & CO
PLBC PLUMAS BANCORP
CNBKA CENTURY BANCORP INC. CL A
MRAM EVERSPIN TECHNOLOGIES
RARX RA PHARMACEUTICALS
T AT&T CORP.
GEMP GEMPHIRE THERAPEUTICS
MX MAGNACHIP SEMICONDUCTOR CORP.
MGEN MIRAGEN THERAPEUTICS
KALA KALA PHARMACEUTICALS INC.
BCO THE BRINK'S COMPANY
ODT ODONATE THERAPEUTICS INC
CCUR CONCURRENT COMPUTER CORPORATION
COGT FLUENT INC
CHN THE CHINA FUND
PBIP INC.
CTIC PRUDENTIAL BANCORP
MBL CELL THERAPEUTICS
SMPL INC.
CODA M B T FINANCIAL CORP.
SSTI SIMPLY GOOD FOODS CO
CODA OCTOPUS GROUP INC.
SHOTSPOTTER
- Jonathan Moreland
WFC WELLS FARGO & COMPANY
TICC OXFORD SQUARE CAPITAL CORP
SYNL SYNALLOY CORP.
RDUS RADIUS HEALTH INC.
PBH PRESTIGE CONSUMER HEALTHCARE INC
OPK OPKO HEALTH INC.
ONTX ONCONOVA THERAPEUTICS INC
MAA MID-AMERICA APARTMENT COMMUNITIES INC.
JWN NORDSTROM INC.
IVAC INTEVAC INC.
FLDM FLUIDIGM
EPC EDGEWELL PERSONAL CARE CO.
ENTA ENANTA PHARMACEUTICALS INC.
EGP EASTGROUP PROPERTIES INC.
BZH BEAZER HOMES USA INC.
BOCH BANK OF COMMERCE HOLDINGS
AHH ARMADA HOFFLER PROPERTIES INC.
BW BABCOCK & WILCOX ENTERPRISES
GRA W R GRACE & CO
CNBKA CENTURY BANCORP INC. CL A
T AT&T CORP.
GEMP GEMPHIRE THERAPEUTICS
NYMX NYMOX PHARMACEUTICAL CORP.
KALA KALA PHARMACEUTICALS INC.
PFIN P AND F INDUSTRIES
CHN THE CHINA FUND
CZWI INC.
PBIP CITIZENS COMMUNITY BANCORP (EAU CLAIRE
SLGD WI)
CTIC PRUDENTIAL BANCORP
MBL SCOTT'S LIQUID GOLD INC.
TRV CELL THERAPEUTICS
PHIL INC.
M B T FINANCIAL CORP.
THE TRAVELERS COMPANIES
INC.
PHI GROUP INC.
Two Directors bought 85,715 shares at 7.000USD.
Two Directors at Gemphire Therapeutics Inc bought 85,715 shares at 7.000USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.